Last reviewed · How we verify
Baminercept alfa 1
At a glance
| Generic name | Baminercept alfa 1 |
|---|---|
| Also known as | BG9924, LT beta |
| Sponsor | Biogen |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome (PHASE2)
- 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (PHASE2)
- Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baminercept alfa 1 CI brief — competitive landscape report
- Baminercept alfa 1 updates RSS · CI watch RSS
- Biogen portfolio CI